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Abstract
Background: Cardiovascular disease (CVD) and colon cancer incidence are known to be closely
related to dietary factors. This article evaluated effects of krill oil (KO) on serum lipids of
hyperlipidemia rats and human colon cancer cells (SW480). Serum lipids of rats fed with high fat
diet (HFD) and different doses of KO were measured by automatic analyzer. Effect of KO on
viability of cells was determined by methyl thiazolyl tetrazolium (MTT) assay.
Results: Except for higher dose group, body weights decreased significantly. Total cholesterol
(TC), LDL-cholesterol (LDL-C) of all dose groups, Triglycerides (TG) of low and mid dose groups
descended significantly, while there were no significant differences of HDL-cholesterol (HDL-C),
compared with control group. Treatment of colon cancer cells with KO also resulted in time-
dependent inhibition of cell growth.
Conclusion: Our findings indicated that the consumption of KO may provide benefits to control
serum lipid levels in certain diseases and inhibit growth of colon cancer cells. Therefore, KO may
be a good candidate for development as a functional food and nutraceutical.
Background
Antarctic Krill are ancestors of clayfish and prawn. They
have a slow evolutionary speed, and are not good at swim-
ming. They are distributed in Vancouver saigan sea area,
Russia, Ukraine and so on. They have the largest amount
of protein among all organisms so far, over 16% in wet
weight while over 65% in dry weight. Antarctic KO con-
tain more than 30% of essential eicosapentaenoic acid
(EPA, C:20:5, n-3) and docosahexaenoic acid (DHA,
C:22:6, n-3) as well as astaxanthin (provitamin E) in con-
centrations of 200 – 400 ppm [1]. Besides, they also have
abundant phospholipids, flavonoids, vitamin A, Alpha-
linolenic acid (ALA), astacin and other nutrients [2].
Cardiovascular disease (CVD) and colon cancer incidence
are known to be closely related to dietary factors [3]. As
the modern medical science indicated, CVD had become
the first killer of people's health. And diabetes, CVD and
hypertension often cluster [4,5]. All kinds of dangerous
factors, including change of life style, dietetic habit, indi-
cate that the morbidity of coronary heart disease in China
will rise quickly in the future. The latest survey of nutri-
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tional and health conditions of the citizens showed, prev-
alence of abnormal lipids among adults in China was
18.6%. Several recommendations based on experimental,
epidemiological or nutritional data had shown that the
incidence of CVD was positively correlated with saturated
fatty acids intake and negatively with unsaturated fatty
acids intake [6]. Controlled intervention trails with encap-
sulated fish oil supplements containing EPA plus DHA
have established their triglyceride-lowering effects and
modifying influence on other CVD risk factors independ-
ent of blood lipid-lowering [7,8]. Cancer chemopreven-
tion has emerged as an important way to control cancer by
using dietary agents capable of blocking neoplastic incep-
tion or delaying disease progression [9]. Research indi-
cated that this strategy was promising on reducing the
morbidity of cancer in high-risk population and in the
common group [10]. In the recent years, the role of nutri-
ents as chemopreventive agents has been the focus of cur-
rent world. The idea of using natural extracts for the
chemoprevention of cancer was obtained from animal
models, clinical trials, human epidemiologic studies and
cell studies [11]. Colon cancer is the second most com-
mon cause of cancer deaths in the USA, with an estimated
annual incidence of 104,950 and mortality of 56,290 in
2005. The incidence of colon cancer is also constantly
increasing in Asia [12]. A lot of effective methods and
measures had been on service to reduce the mortality of
colon cancer. Using naturally compounds present in die-
tary sources for chemoprevention is considered as a prac-
tical hopeful approach.
Some compounds have undergone clinical trials against
colon cancer based on this idea [13,14]. The anti-cancer
properties of KO are currently under investigation to see
whether it can block or delay the malignant progression of
transformed cells by modulating cell proliferation or dif-
ferentiation. The cytostatic effect could be attained by the
ingestion of KO on human colon carcinoma cell. There-
fore, we studied whether KO had potential to slow the
proliferation rates via programmed cell death. At present,
studies are mainly focusing on the distribution, biological
and physiological characteristics of Krill resources, few on
the functional characteristics of KO. Therefore, the aim of
this study was to evaluate the antilipidemic and anti-can-
cer effects of KO.
Results
Establishment of hyperlipidemia rats model
The results showed that the total TC, TG, and LDL-C of
serum of rats significantly increased (P < 0.05) after 2
weeks of HFD, while high HDL-C decreased significantly
(P < 0.05) compared with pre-feeding. It indicated the
hyperlipemia models were established successfully. Thus,
the following experiment was feasible.
Effects of KO on body weights
Our study showed that, there were no significant differ-
ences, in body weight levels in other groups compared
with the control group before administration (Figure 1).
On the other hand, after four weeks' treatment with KO
and lovastatin, diversity was observed. Except for Higher
dose group, the body weight was decreased in each group
obviously compared with control (p < 0.05). Among
them, the difference between medication and control
group was up to super remarkable level (p < 0.01). In
addition, compared with medication group, there were no
diversities in low, mid and high dose groups.
Effects on the lipid levels
TG, TC, HDL-C and LDL-C levels in serum before and
after administration of KO were analysed. Significant
changes in serum lipids were observed after 4 week con-
sumption of KO. The intake of KO for 4 weeks had a low-
ering effect on TG, TC and LDL-C, while no changes were
observed in HDL-cholesterol. All doses of KO could sig-
nificantly decrease the TC (Figure 2), TG (Figure 3) and
LDL-C (Figure 5) level of serum (P < 0.05) after 4 weeks
of KO; high and higher doses of KO could significantly
increase the HDL-C (Figure 4) levels. And compared with
the hyperlipidemia control group, TC and LDL-C of all
dose groups, TG of low and mid dose groups decreased
significantly (p < 0.05), and no remarkable differences
were observed. It indicated that KO could decrease TC, TG
and LDL-C levels of serum significantly. On the other
hand, it had little influence on serum HDL-C.
Anti-cancer effect
As was shown in Figure 6, treatment of SW480 cells with
2.5, 5, 10, 15, 20 μg/ml concentrations of KO for 48 h,
Effqects of KO on body weights of rats Figure 1
Effects of KO on body weights of rats. The body weight 
of experimental rats (  ± s, g, n = 10) in the third (3rd w) 
and seventh (7th w) weeks. *, p < 0.05, compared with high 
lipid model control group; **, p < 0.01, compared with high 
lipid control group; a, p < 0.05, compared with medication 
group.
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resulted in 15.2%, 20.6%, 22.0%, 24.6% and 29.9% inhi-
bition of cell growth respectively, compared with vehicle
treated control. Exposure of SW480 cells to KO resulted in
slight decrease in cell viability at the highest concentration
of 50 μg/ml (data not shown). Treatment of colon cancer
cells with KO also resulted in time-dependent inhibition
of cell growth, and the effect was more pronounced at 72
h post-treatment. The inhibition rates were 16.7%,
23.4%, 26.7%, 27.2% and 30.9%, respectively. While in
120 h, the numbers were 19.7%, 24.2%, 28.0%, 30.8%
and 33.5%, respectively.
Discussion
It suggested that administration of KO caused significant
change in body weight and the KO had good weight lose
effect similar to the lipid-reducing medicine. It has also
been reported that different types of fatty acids have differ-
ent effects on body weight gain and insulin resistance. Sat-
urated fatty acids (SFAs) produce more weight gain and
insulin resistance than polyunsaturated fatty acids
(PUFAs) in some studies [15,16]. Of all the PUFAs, EPA
and DHA exert more favorable influence on body weight
[17]. It was reported body weight of the diet group supple-
Effects of KO on LDL-Cholesterol content Figure 5
Effects of KO on LDL-Cholesterol content. Serum Lip-
ids levels obtained after treatments with KO and lovastatin. 
The rats were fed for 4 weeks continuously. Data were mean 
values ± std for 10 rats.
Effects of KO on Triglycerides content Figure 3
Effects of KO on Triglycerides content. Serum Lipids 
levels obtained after treatments with KO and lovastatin. The 
rats were fed for 4 weeks continuously. Data were mean val-
ues ± std for 10 rats.
Effects of KO on Total Cholesterol content Figure 2
Effects of KO on Total Cholesterol content. Serum 
Lipids levels obtained after treatments with KO and lovasta-
tin. The rats were fed for 4 weeks continuously. Data were 
mean values ± std for 10 rats.
Effects of KO on HDL-Cholesterol content Figure 4
Effects of KO on HDL-Cholesterol content. Serum Lip-
ids levels obtained after treatments with KO and lovastatin. 
The rats were fed for 4 weeks continuously. Data were mean 
values ± std for 10 rats.Lipids in Health and Disease 2008, 7:30 http://www.lipidworld.com/content/7/1/30
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ment with fish oil increased by 25% [18]. Fatty acids
derived from fish oil had been shown to alter proinflam-
matory cytokine production and acute-phase protein
(APP) synthesis in vitro. The presence of APP has been
suggested to contribute to weight loss. The administration
of PUFAs to hepatocytes had suggested that EPA may have
direct effects on the modulation of APP production [19].
The mechanism of the KO used in the present study and
the relative contributions of its components requires fur-
ther study.
The present study proved that KO could significantly
decrease the TC, TG and LDL-C levels of serum, while
slightly increase the HDL-C levels as well. It was reported
the long-term intake of egg-white hydrolysed (hEW) for
20 weeks had a lowering effect on TG and TC, while no
changes were observed in HDL-C [20]. It was also found
that some natural active substances could significantly
decrease the TC, TG and LDL-C levels, but there were no
significance in HDL-C [21,22]. A great deal of findings
indicated that EPA and DHA could reduce body blood TG,
TC and LDL-C. It had been reported that fish oil had cho-
lesterol-lowering effect because it increased DHA content
in the membrane and could improve membrane fluidity.
Thus, it increased removal rate of VLDL-C and LDL-C par-
ticles from plasma by improving hepatic microsomal
membrane fluidity, and thus, it decreased the TG, TC,
LDL-C significantly. But it didn't increase the HDL-C level.
Unlike fish oil and KO, corn oil significantly increased
plasma HDL-C levels and reduced the risk factor for CVD
since HDL-C had the important role of reversing choles-
terol transport [23]. The reason may be the difference of
various food composition, operation mechanism, or dif-
ferent animal study itself (great individual differences),
the complex of metabolism of HDL-C and so on.
As far as we know, this is the first report showing the anti-
cancer effect of KO on human colon cancer cells. How-
ever, more detailed studies are required to determine the
exact mechanism(s). KO contains four constituents which
may reduce the risk of developing the colon cancer: EPA,
DHA, ALA, sphingolipid. Many reports indicated that EPA
and DHA could inhibit the growth of some cancer cells,
such as breast, prostate cancer [24,25]and so on. Fish oil
was known to reduce growth of certain tumors, such as
colon, breast and prostate cancers [26]. These effects were
attributed to the content of PUFAs of the n-3 family in fish
oil, in particular EPA and DHA, which regulate cellular
signaling paths. Several PUFAs are known regulators of
the ligand-activated transcription factors known as perox-
isome proliferators-activated receptors (PPARs) [27].
Originally implicated in the regulation of lipid metabo-
lism and adipocyte differentiation, the PPARs have also
been implicated in cell differentiation, cell proliferation,
and in inflammatory responses [5,25]. However, the
mechanism(s) underlying of the anti-cancer effects were
not fully understood. ALA alters the fatty acid composi-
tion of cell membranes in crucial ways and inhibits the
release of pro-inflammatory eicosanoids, which control
the growth and invasiveness of tumor cells and modulate
the cycle of cell apoptosis among the many factors [28].
As was known, sphingomyelin which existed in cell
plasma membrane of most mammalian was the main
component of myelin sheath. It was rich in cell membrane
of brain and nerve. Several studies had demonstrated
altered total sphingolipid composition, both increases
and decreases, in cancer cells. It is unclear what effect
changes in sphingolipid composition and metabolism(s)
have on the sensitivity of cancer cells to therapy. It was
reported that dietary sphingomyelin protected against
apoptosis and hyperproliferation caused by the hydro-
phobic bile salt deoxycholate potential implications for
colon cancer. They thought the use of sphingomyelin to
boost the chemotherapy response of cancer cells could
have a significant impact on treatment outcome [29].
Numerous epidemiologic studies have provided a gist for
the development cancer chemoprevention protocols
using bio-active dietary agents capable of eliminating pre-
malignant or malignant cells. The results of this study sug-
Effect of KO on cell viability time-dependent in human colon  cancer SW480 cells Figure 6
Effect of KO on cell viability time-dependent in 
human colon cancer SW480 cells. The cells were 
exposed to the specified concentration of KO for 48 h, 72 h 
and 120 h, and viability of cells were determined by MTT 
assay. Cell viabilities were described as percentages; vehicle-
treated cells were regarded as 100% viable. Details were 
described in methods.Lipids in Health and Disease 2008, 7:30 http://www.lipidworld.com/content/7/1/30
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gested KO had the potential to affect the steady state cell
population.
Conclusion
The main finding of this study was that the treatment with
KO reduced the body weight and serum TG, TC and LDL-
C levels significantly. The results showed hypolipidemic
properties and thus, the consumption of KO may provide
benefit to control serum lipid levels in certain diseases. In
addition, KO affected the steady state cell population to
inhibit growth of colon cancer and thus may be a good
candidate for development as a chemopreventive and/or
therapeutic agent against colon cancer. In a word, it is




The krill oil was purchased from local market. The oil was
placed at the refrigerator with the temperature of -20°C.
Distilled water was added to Ryoto sugar ester (S-1170F,
Mitsubishi-Kagaku Foods Corporation) to make the con-
centration 5 g/L, and then the solution was mixed for 10
minutes at the speed of 1500 rpm using magnetic whisk
mix. The final solution was used as the solvent for KO to
make desired samples for rats.
Cell lines
Human colon cancer cells, SW480 were purchased from
Stem Cell Bank, Chinese Academy of Sciences, and were
propagated in the recommended medium. And the cells
were cultured in RPMI 1640 medium with 10% FBS and
1% penicillin streptomycin (GIBCO) at 37°C in a incuba-
tor of humidified atmosphere with 5% CO2.
Animal study
Sixty adult male SD rats, weighing 180 ~ 190 gram each,
were purchased from Zhejiang Academy of Medical Sci-
ence, and divided into six groups. Ten rats of each group
were housed in one cage and fed in the center for experi-
mental animals of Zhejiang University with the room
temperature (25 ± 2)°C and humidity (63 ± 2)%. The
HFD was composed of 78.8% common feed, 1% choles-
terol, 10% yolk powder, 10% lard and 0.2% cholate. Body
weights and feed intakes were recorded every three days
during the next seven weeks. Following was the animal
study procedure: SD rats were kept in SPF animal experi-
ment lab for 1 week with fundament diet. Serum samples
were taken from rats' tails and centrifuged at 3000 rpm for
15 min at 4°C for the analysis of TC, TG, HDL-C and LDL-
C levels. Then rats were fed with HFD for 2 weeks to estab-
lish the hyperlipidemia model according to TC, TG, HDL-
C and LDL-C levels. And then the rats were divided into 6
groups according to the TC levels randomly. The low dose
group was given HFD with 16.65 g/L of KO, and the mid
dose, the high dose and the higher dose groups were feed
by HFD supplemented with 33.3 g/L, 99.9 g/L and 199.8
g/L of KO, respectively. The high lipid control was given
HFD with the same volume solvent. The dosages of KO
were 0.5 ml/100 g body weight of experimental rats. And
the medication group was treated with lovastatin 100 mg/
kg/day. Serum from 12 h-fasting rats' tails was taken after
1 w, 3 w and 7 w. The analysis of TC, TG, HDL-C and LDL-
C were measured by automatic hitachi-7170 analyzer.
Cell proliferation assay
The effect of KO on the viability of cells was determined
by methyl thiazolyl tetrazolium (MTT) (3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyl tetra zoliumbromide) assay. In
short, the cells were plated at 1 × 104 cells per well in 200
μl of complete culture medium containing 0, 2.5, 5, 10,
15, and 20 μg/ml concentrations of KO in 96-well micro-
titer plates. The KO solutions were dissolved in anhydrous
ethanol and mixed with aseptic PBS to achieve the desired
final concentration. Each concentration of KO was
repeated in ten wells. After incubation at 48 h, 72 h, 120
h in the incubator, cell viability was determined. Twenty
microlitres MTT (5 mg/ml in phosphate-buffered saline
stock, diluted to working strength 1 mg/ml with media)
was added to each well and incubated for 4 h. After that,
the MTT solution was removed from the wells by careful
aspiration. Then, 200 μl of buffered DMSO was added to
each well and plates were well-mixed. The absorbance was
recorded on a microplate reader at the wavelength of 490
nm. The effect of KO on growth inhibition was evaluated
as percent cells viability where vehicle KO-treated cells
were considered as 100% survival.
Statistical analysis
All data were handled with SPSS package program version
11.0 (SPSS, Chicago, IL). The results were listed in the way
of mean ± std (  ± s), and the significance between the
control and treated groups was performed using ANOVA
Statistical analysis. Differences were considered signifi-
cant at P < .05.
List of abbreviations used
ALA: alpha-linolenic acid; CVD: cardiovascular disease;
DHA: docosahexaenoic acid; EPA: essential eicosapentae-
noic acid; HFD: high fat diet; KO: krill oil; MTT: methyl
thiazolyl tetrazolium; PPARs: peroxisome proliferators-
activated receptors.
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